Danish Drama: Genmab Drops $8B on Cancer Cure Hope Seller
In a move that screams 'we have billionaire money to burn,' Danish biotech bigwig Genmab announced it plans to acquire Merus, the brainiac behind a shiny new head and neck cancer drug, for around $8 billion. That's $8 billion, or roughly the cost of buying every Danish pastry in Copenhagen twice over. This deal lands Genmab firmly in Life Sciences prime, scheming to turn biology into cold, hard kroner. With cancer therapy innovation like this on the line, letās hope Merus's drug fights neck and head tumors better than Genmab fought that price tag.
Share the Story
Genmab just dropped $8 billion on Merus like itās Black Friday for biotech, apparently 'saving cancer patients' is easier when you have a billionaire bankroll appearing out of nowhere.
Buying a head and neck cancer drug developer for $8 billion is peak pharmaceutical flexāGenmabās basically saying, 'Weāll fix your cells, but first, show us the money.'
Genmab buying Merus is like paying $8 billion for a Tesla upgradeāyouāre still hoping it doesnāt break down, but hey, it looks promising!
Source: Statnews | Published: 9/29/2025 | Author: Andrew Joseph
More Articles in Business
Salesforce AI Flops, Google Car-Dwellers & Senior Homebuyers Take Over
KPMGās 450K Sq.Ft NYC HQ: Employee Feedback or Round Table Cult?
Rivian CEOās $4.6B Stock Option: Billionaire or Billion Procrastinator?
DoorDash Execs Fail at Delivery, Beta-Test Their Own Chaos
Parenting & Two Jobs: Health Writer Floors Architectural Chaos!
